Close Menu

NEW YORK – Becton Dickinson reported on Tuesday that its fiscal fourth quarter revenues increased approximately 4 percent year over year.

For the three months ended Sept. 30, the company posted revenues of $4.58 billion compared to $4.40 billion in the year-ago quarter, and slightly higher than analysts' average estimate of $4.56 billion. On a currency-neutral basis, Q4 revenues increased about 6 percent over the prior year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.